# Advancing AD Clinical Trials Through Blood-Based Biomarkers & Amyloid PET Webinar 9 Oct 25 webinars # Advancing AD Clinical Trials Through Blood-Based Biomarkers & Amyloid PET Webinar [ ](https://x.com/intent/tweet?url=https://ixico.com/news-and-resources/webinars/advancing-ad-clinical-trials-through-blood-based-biomarkers-and-amyloid-pet-webinar/) [ ](https://bsky.app/intent/compose?text=https://ixico.com/news-and-resources/webinars/advancing-ad-clinical-trials-through-blood-based-biomarkers-and-amyloid-pet-webinar/) [ ](https://www.facebook.com/sharer/sharer.php?u=https://ixico.com/news-and-resources/webinars/advancing-ad-clinical-trials-through-blood-based-biomarkers-and-amyloid-pet-webinar/) [ ](https://www.linkedin.com/shareArticle?mini=true&url=https://ixico.com/news-and-resources/webinars/advancing-ad-clinical-trials-through-blood-based-biomarkers-and-amyloid-pet-webinar/) ![GAB Webinar](/assets/blog-images/GAB-Webinar__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp)We join the Global Alzheimer's Platform Foundation's (GAP) Chief Commercial Officer, Lammert Albers, hosted a webinar with OurChief Scientific Officer, Robin Wolz, and Fujirebio's Director of Clinical Research and Development, Rachel Radwan, on the importance of collaboration in advancing AD clinical trials with the joint use of Blood-Based Biomarkers and Amyloid PET imaging. [ Back to Webinars ](/news-and-resources/webinars/) ### Recents ![Where Vascular Disease and Alzheimer’s Meet: Shared Pathways to Cognitive Decline ](/assets/blog-images/AD-Webinar-2026-1__ScaleMaxWidthWzgwMF0_FillMaxWzgwMCw0NTBd_ExtRewriteWyJwbmciLCJ3ZWJwIl0.webp) 1 Oct 26 webinars [Where Vascular Disease and Alzheimer’s Meet: Shared Pathways to Cognitive Decline ](/news-and-resources/webinars/where-vascular-disease-and-alzheimers-meet-shared-pathways-to-cognitive-decline/) [Understanding Imaging in Parkinson’s Disease Trials: From Eligibility to Efficacy](/news-and-resources/webinars/understanding-imaging-in-parkinsons-disease-trials-from-eligibility-to-efficacy/) [Endpoint selection in Huntington’s disease trials: how neuroimaging advances drive better outcomes](/news-and-resources/webinars/endpoint-selection-in-huntingtons-disease-clinical-trials-and-how-advances-in-neuroimaging-can-drive-better-trial-outcomes/) [Alzheimer’s Landscapes: Comorbidities, Novel Targets, and Imaging Through the Neuroradiologist’s Lens](/news-and-resources/webinars/alzheimers-landscapes-comorbidities-novel-targets-and-imaging-through-the-neuroradiologists-lens/) [Parkinson's Disease: Unveiling the Promise of Neuromelanin Sensitive Imaging](/news-and-resources/webinars/parkinsons-disease-unveiling-the-promise-of-neuromelanin-sensitive-imaging/) ### Library [November 2026](/news-and-resources/webinars/archive/2026/11/) [October 2026](/news-and-resources/webinars/archive/2026/10/) [September 2026](/news-and-resources/webinars/archive/2026/09/) [July 2026](/news-and-resources/webinars/archive/2026/07/) [June 2026](/news-and-resources/webinars/archive/2026/06/) [May 2026](/news-and-resources/webinars/archive/2026/05/) [April 2026](/news-and-resources/webinars/archive/2026/04/) [March 2026](/news-and-resources/webinars/archive/2026/03/) [February 2026](/news-and-resources/webinars/archive/2026/02/) [January 2026](/news-and-resources/webinars/archive/2026/01/) [2025](/news-and-resources/webinars/archive/2025/) [2024](/news-and-resources/webinars/archive/2024/) [2023](/news-and-resources/webinars/archive/2023/) [2022](/news-and-resources/webinars/archive/2022/) [2021](/news-and-resources/webinars/archive/2021/) [2020](/news-and-resources/webinars/archive/2020/) [2019](/news-and-resources/webinars/archive/2019/)